PPT-Peginterferon alfa-2a Drugbank

ID DB00008 Protein average weight 600000000 Half life Terminal half life is 80 hours range 50 to 140 hours Description Human interferon 2a is a covalent conjugate of recombinant alfa2a interferon with a single branched . 2 Alfa pendant light engines featurefour high-output, low-power LEDsproduce warm, elegant, dimmablelight with CRI greater than 80 and Alfa LED pendants are 12V fixturesand can be installed on a divers Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of the Alfa Laval spiral heat exchangers Problem solvers for tough applications 2 Alfa Laval – spiral heat exchangers severe fouling. When it’s nally time for maintenance SHEs are considerably sa Genotype . 1 . (. Viral . Relapsers. ). PROMISE . Trial. Phase . 3. Treatment. . Experienced. Forns. X. , . et al. . Gastroenterology. 2014;146:1669-79.e3.. Source: . Forns. X. , et al. Gastroenterology. 2014;146:1669-79.e3.. versus . Telaprevir. . with PR in GT1 . ATTAIN Trial. Phase . 3. Treatment. . Experienced. Reddy KR. , . et al. . Lancet Infect Dis. 2015;15:27-35.. Source: Reddy KR. , et al. Lancet Infect Dis. 2015;15:27-35.. alfa-2a . versus. . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. Pegasys. ). Prepared by: David Spach, MD & H. Nina Kim, MD. Last Updated: February . 14, . 2014. Background and Dosing. Peginterferon alfa-2a (. Pegasys. ). Peginterferon alfa-2a (. Pegasys. ). Summary. Phase 3. Treatment. . Naïve, Chronic HCV. McHutchison. . JG, et al. N . Engl. J Med. 1998;339:1485-92.. I. nterferon . alfa-. 2b . +/- Ribavirin for Chronic HCV. Study . Outline. Study. -. . Randomized, double-blinded, placebo controlled, phase 3 trial. Using . SiPM. to readout Scintillating Fibers . What has been done for ALFA. The “Scintillating Fibers & . SiPM. ” status of the art. . ALFA. . SiPM. Collecting Information. Starting discussion. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . RBV . versus. Interferon alfa. -. 2a + RBV . ACTG 5071. Phase . 2. Treatment. . Naïve, Chronic HCV and HIV. Chung RT, . et. al. N . Engl. J Med. . 2004;351:451-9. . PEG alfa. -2a . + . RBV . versus. Molinuevo. , Craig Ritchie, . Miia. . Kivipelto. tribeka.org. @. TRIBEKAplatform. The. . TriBEKa. . imaging. . consortium. Barcelona-Edinburgh-. Karolinska. The . mission. of the consortium is to generate an . . PEG alfa-. 2a . versus. INF RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . . RBV . versus. . PEG . C. 809. H. 1301. N. 229. O. 240. S. 5. 18.2 . kDa. DESCRIPTION. INDICATION. The active substance in . Epoetin. zeta is a recombinant human erythropoietin (. rhEPO. ) of identical primary structure produced in Chinese Hamster Ovary (CHO) cells. The molecular weight of the .